Company No:
Contents
| Note | 31.12.2024 | |
| £ | ||
| Fixed assets | ||
| Investments | 3 |
|
| 100 | ||
| Current assets | ||
| Debtors | 4 |
|
| 399,188 | ||
| Net current assets | 399,188 | |
| Total assets less current liabilities | 399,288 | |
| Net assets |
|
|
| Capital and reserves | ||
| Called-up share capital | 5 |
|
| Share premium account |
|
|
| Total shareholders' funds |
|
Directors' responsibilities:
The financial statements of Amica Scientific (Holdings) Limited (registered number:
|
A C Wadsworth
Director |
The principal accounting policies are summarised below. They have all been applied consistently throughout the financial period, unless otherwise stated.
Amica Scientific (Holdings) Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is Turner Heath, 103 Bollington Road, Bollington, SK10 5EL, United Kingdom.
The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.
The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.
Assets, other than those measured at fair value, are assessed for indicators of impairment at each Balance Sheet date. If there is objective evidence of impairment, an impairment loss is recognised in the Statement of Income and Retained Earnings as described below.
The company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investment in non-puttable ordinary shares.
Investments in subsidiaries are measured at cost less accumulated impairment
| Period from 21.09.2023 to 31.12.2024 |
|
| Number | |
| Monthly average number of persons employed by the Company during the period. |
|
The directors did not receive any remuneration in the period.
Investments in subsidiaries
| 31.12.2024 | |
| £ | |
| Cost | |
| At 21 September 2023 | 0 |
| Additions |
|
| At 31 December 2024 |
|
| Carrying value at 31 December 2024 |
|
| 31.12.2024 | |
| £ | |
| Amounts owed by Group undertakings |
|
| Other debtors |
|
|
|
| 31.12.2024 | |
| £ | |
| Allotted, called-up and fully-paid | |
|
|
|
|
|
|
|
|
|
|
|
|
| 100 |
On 5 December 2023, the company issued 24 A Ordinary shares at £1 each, 25 B Ordinary shares at £1 each and 25 C Ordinary shares at a premium.
On 16 April 2024, the company issued 25 D Ordinary shares at a premium.